

C. Grace Yeh, Ph.D.

葉常菁博士

President and Chief Executive Officer
PharmaEngine, Inc.



Dr. Grace Yeh is President and Chief Executive Officer of PharmaEngine, Inc., a publicly traded commercial stage oncology company which she founded in Taipei, Taiwan in 2003. The company established a wholly owned subsidiary, PharmaEngine Europe, Sarl, in Paris, France, in 2015.

PharmaEngine focuses on developing new drugs for cancer and Asian prevalent diseases. The company has adopted the no research development only (NRDO) and networked pharma models. PharmaEngine has three corporate partners (Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA; Nanobiotix S.A., Paris, France; and Guangzhou BeBetter Technology Co., Ltd., Guangzhou, China). The company has received numerous awards.

Prior to returning to Taiwan, she served as Vice President of Development Project Leadership at Millennium Pharmaceuticals, Inc.; Vice President of Preclinical Drug Development at LeukoSite, Inc.; Chief Scientific Officer at CytoMed, Inc; and Director of Pharmaceutical Evaluation at T Cell Sciences, Inc., all in Cambridge, MA, USA. Prior to joining industry, she worked in academic research at INSERM (National Institutes of Health and Medical Research) in France and Blond McIndoe Centre for Transplantation Biology in England.

During her career, Dr. Yeh has participated in the discovery, preclinical, and clinical development of recombinant proteins, monoclonal antibodies and small molecules for the treatment of cancer, inflammation, allergy, cardiovascular, and metabolic diseases in the US, Europe and Asia.

Dr. Yeh received her B.S. in Biology from Fu-Jen University, Taiwan, and her Ph.D. in Immunology from Medical University of South Carolina, USA. She has over 70 peer-reviewed publications and 6 issued US patents.